Bayer Ag · XETR:BAYN

Bayer — Technical Presentation (October 2023)

12 slides from Bayer's technical presentation, October 2023

1. Slide 1: Baseline Characteristics of Patients Who Did or Did Not Maintain 12- & 16-Week Aflibercept 8 mg Dosing Intervals

   Baseline Characteristics of Patients Who Did or Did Not Maintain 12- & 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial Kiyoshi Suzuma,1 on behalf of the PHOTON study investigators 1Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan Presented at

2. Slide 2: Disclosures

   Disclosures • Professor Suzuma receives research fees from Alexion, Alvotech, Bayer, Chugai, and Novartis; DME scholarship donations from Alcon, AMO, HOYA, Kowa, Otsuka, Santen, Senju and Wakamoto; consultancy fees from Chugai, Nippon Boehringer, and Senju; and lecture fees from Alcon, AMO, Bayer, C

3. Slide 3: PHOTON: Study Design and Dosing Schedule

   PHOTON: Study Design and Dosing Schedule DME

4. Slide 4: PHOTON: 48-Week BCVA Primary Endpoint Met in Both 8 mg Groups

   PHOTON: 48-Week BCVA Primary Endpoint Met in Both 8 mg Groups DME

5. Slide 5: Proportion of 8 mg Patients Maintaining Q12- and Q16-Week Intervals Through Week 48

   Proportion of 8 mg Patients Maintaining Q12- and Q16-Week Intervals Through Week 48 DME 93% of 8 mg patients maintained dosing intervals ≥12 weeks

6. Slide 6: Baseline Demographics by Dosing Interval

   Baseline Demographics by Dosing Interval DME

7. Slide 7: Baseline Demographics by Dosing Interval

   Baseline Demographics by Dosing Interval DME

8. Slide 8: Baseline Ocular Characteristics by Dosing Interval

   Baseline Ocular Characteristics by Dosing Interval DME

9. Slide 9: Univariable Analysis: Baseline Characteristics Associated with the Incidence of Dosing Interval Shortening

   Univariable Analysis: Baseline Characteristics Associated with the Incidence of Dosing Interval Shortening DME

10. Slide 10: Multivariable Analysis: Baseline Characteristics Associated with the Incidence of Dosing Interval Shortening

    Multivariable Analysis: Baseline Characteristics Associated with the Incidence of Dosing Interval Shortening DME

11. Slide 11: Absolute BCVA and CST at Baseline and Week 48 by Dosing Interval

    Absolute BCVA and CST at Baseline and Week 48 by Dosing Interval DME

12. Slide 12: Conclusions

    Conclusions + Aflibercept 8q12 and 8q16 demonstrated non-inferior BCVA gains compared to aflibercept 2q8 at Week 48, with a large majority of patients maintaining their randomized 12- or 16-week dosing intervals — Dosing intervals were shortened in approximately 10% of patients + Lower BCVA and grea

Bayer — Technical Presentation (October 2023) on 6ix